The role of microvascular injury in the evolution of idiopathic pulmonary fibrosis

American Journal of Clinical Pathology

Volumn 119, Issue 4, 2003, Pages 556-567

  Magro, Cynthia M ^a   Allen, James ^a   Pope Harman, Amy ^a   Waldman, W James ^a   Moh, Patrick ^a   Rothrauff, Susan ^b   Ross Jr , Patrick ^a,b  

^a OHIO STATE UNIVERSITY   (United States)

^b Biomedical Engineering Group   (United States)

Author keywords

Antiendothelial cell antibodies; Antiphospholipid antibodies; Idiopathic pulmonary fibrosis; Microvascular injury

Indexed keywords

ANTIBODY; BLOOD CLOTTING FACTOR 8; CELL ANTIBODY; GLYCOPROTEIN; PHOSPHATIDYLETHANOLAMINE; PHOSPHATIDYLSERINE; PHOSPHOLIPID ANTIBODY; VIRUS DNA; ANTINUCLEAR ANTIBODY; RIBONUCLEOPROTEIN; SS A ANTIBODIES; SS-A ANTIBODIES; VIRUS RNA;

ADULT; ARTICLE; CLINICAL ARTICLE; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; FEMALE; HUMAN; HUMAN TISSUE; HUMORAL IMMUNITY; IDIOPATHIC DISEASE; IMMUNOFLUORESCENCE; IN SITU HYBRIDIZATION; LUNG FIBROSIS; LUNG PARENCHYMA; MALE; MICROANGIOPATHY; PARVOVIRUS; PATHOGENESIS; PRIORITY JOURNAL; SERODIAGNOSIS; UNITED STATES; VIRUS INFECTION; BLOOD; CYTOMEGALIC INCLUSION BODY DISEASE; FLUORESCENT ANTIBODY TECHNIQUE; GENETICS; IMMUNOLOGY; ISOLATION AND PURIFICATION; LUNG; METABOLISM; MICROCIRCULATION; MIDDLE AGED; PATHOLOGY; VASCULAR ENDOTHELIUM; VASCULARIZATION; VIROLOGY;

ADULT; ANTIBODIES, ANTINUCLEAR; ANTIBODIES, ANTIPHOSPHOLIPID; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; DNA, VIRAL; ENDOTHELIUM, VASCULAR; FACTOR VIII; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE, DIRECT; HUMANS; IN SITU HYBRIDIZATION; LUNG; MALE; MICROCIRCULATION; MIDDLE AGED; PARVOVIRIDAE INFECTIONS; PARVOVIRUS B19, HUMAN; PULMONARY FIBROSIS; RIBONUCLEOPROTEINS; RNA, VIRAL;

EID: 85047689270     PISSN: 00029173     EISSN: None     Source Type: Journal    
DOI: 10.1309/0B06Y93EGE6TQ36Y     Document Type: Article

References (68)

1. Katzenstein AL, Myers JL. Idiopathic pulmonary fibrosis: to biopsy or not to biopsy [editorial]. Am J Respir Crit Care Med. 2001;164:185-186.
2. Katzenstein AL, Myers JL. Nonspecific interstitial pneumonia and the other idiopathic interstitial pneumonias: classification and diagnostic criteria [editorial]. Am J Surg Pathol. 2000;24:1-3.
3. Kissel JT, Halterman RK, Rammohan KW, et al. The relationship of complement-mediated microvasculopathy to the histologic features and clinical duration of disease in dermatomyositis. Arch Neurol. 1991;48:26-30.
4. Crowson AN, Magro CM. The role of microvascular injury in the pathogenesis of cutaneous lesions of dermatomyositis. Hum Pathol. 1996;27:15-19.
5. Pitonni V, Isenberg D. Apoptosis and antiphospholipid antibodies. Semin Arthritis Rheum. 1998;28:163-178.
6. Rauch J, Subang R, D'Agnillo P, et al. Apoptosis and the antiphospholipid syndrome. J Autoimmun. 2000;15:231-235.
7. Levine JS, Koh J, Suband R, et al. Apoptotic cells as immunogen and antigen in the antiphospholipid syndrome. Exp Mol Pathol. 1999;66:82-98.
8. Magro CM, Crowson AN, Nuovo G, et al. Parvoviral infection of endothelial cells and its possible role in vasculitis and autoimmune diseases. J Rheumatol. 2002;29:1227-1235.
9. Meyer O, Haim T, Cryll A, et al. Vascular endothelial cell injury in progressive systemic sclerosis and other connective tissue diseases. Clin Exp Rheumatol. 1983;1:29-34.
10. Kawanami O, Jiang HX, Mochimaru H, et al. Alveolar fibrosis and capillary alteration in experimental pulmonary silicosis in rats. Am J Respir Crit Care Med. 1995;151:1946-1955.
11. Waldman WJ, Roberts WH, Davis DH, et al. Preservation of natural endothelial cytopathogenicity of cytomegalovirus by propagation in endothelial cells. Arch Virol. 1991;117:143-164.
12. Sambiase NV, Higuchi ML, Nuovo G, et al. CMV and transplant-related coronary atherosclerosis: an immunohistochemical, in situ hybridization, and polymerase chain reaction in situ study. Mod Pathol. 2000;13:173-179.
13. Lewkonia RM, Horne D, Dawood MR. Juvenile dermatomyositis in a child infected with human parvovirus B19. Clin Infect Dis. 1995;21:430-432.
14. Davis G. The pathogenesis of silicosis: state of the art. Chest. 1986;89(3 suppl):166S-169S.
15. Brody AR. Pulmonary cell interactions with asbestos fibers in vivo and in vitro. Chest. 1986;89(3 suppl):155S-159S.
16. Patel A, Ryu J, Reed C. Hypersensitivity pneumonitis: current concepts and future questions. J Allergy Clin Immunol. 2001;108:661-669.
17. Hamman L, Rich AR. Acute diffuse interstitial fibrosis of the lungs. Bull Johns Hopkins Hosp. 1944;74:177-212.
18. Bjoraker JA, Ryu JH, Edwin MK, et al. Prognostic significance of histopathologic subsets in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 1998;157:199-203.
19. Katzenstein AL, Myers JL. Idiopathic pulmonary fibrosis: clinical relevance of pathologic classification. Am J Respir Crit Care Med. 1998;157(4 pt 1):1301-1315.
20. American Thoracic Society. Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS). Am J Respir Crit Care Med. 2000;161(2 pt 1):646-664.
21. Danhiil ZD, Gilchrist FC, Nicholson AG, et al. A histologic pattern of nonspecific interstitial pneumonia is associated with a better prognosis than usual interstitial pneumonia in patients with cryptogenic fibrosing alveolitis. Am J Respir Crit Care Med. 1999;160:899-905.
22. Nagai S, Kitaichi M, Itoh H, et al. Idiopathic nonspecific interstitial pneumonia/fibrosis: comparison with idiopathic pulmonary fibrosis and BOOP. Eur Respir J. 1998;12:1010-1019.
23. Travis WD, Matsui K, Moss J, et al. Idiopathic nonspecific interstitial pneumonia: prognostic significance of cellular and fibrosing patterns: survival comparison with usual interstitial pneumonia and desquamative interstitial pneumonia. Am J Surg Pathol. 2000;24:19-33.
24. Kim TS, Lee KS, Chung MP, et al. Nonspecific interstitial pneumonia with fibrosis: high-resolution CT and pathologic findings. AJR Am J Roentgenol. 1998;171:1645-1650.
25. Hartman TE, Swensen SJ, Hansell DM, et al. Nonspecific interstitial pneumonia: variable appearance at high-resolution chest CT. Radiology. 2000;217:701-705.
26. Johkoh T, Muller NL, Cartier Y, et al. Idiopathic interstitial pneumonias: diagnostic accuracy of thin-section CT in 129 patients. Radiology. 1999;211:555-560.
27. Rossi GA, Hunninghake GW, Kawanami O, et al. Motheaten mice: an animal model with an inherited form of interstitial lung disease. Am Rev Respir Dis. 1985;131:150-158.
28. Hammar SP, Winterbauer RH, Bockus D, et al. Endothelial cell damage and tubuloreticular structures in interstitial lung disease associated with collagen vascular disease and viral pneumonia. Am Rev Respir Dis. 1983;127:77-84.
29. Dobashi N, Fujita J, Murota M, et al. Elevation of anti-cytokeratin 18 antibody and circulating cytokeratin 18:anti-cytokeratin 18 antibody immune complexes in sera of patients with idiopathic pulmonary fibrosis. Lung. 2000;178:171-179.
30. Fujita J, Dobashi N, Ohtsuki Y, et al. Elevation of anti-cytokeratin 19 antibody in sera of the patients with idiopathic pulmonary fibrosis and pulmonary fibrosis associated with collagen vascular disorders. Lung. 1999;177:311-319.
31. Dobashi N, Fujita J, Ohstukin Y, et al. Circulating cytokeratin 8; anti-cytokeratin 8 antibody immune complexes in sera of patients with pulmonary fibrosis. Respiration. 2000;67:397-401.
32. Mineau-Hanschke R, Patton WF, Hechtman HB, et al. Immunolocalization of cytokeratin 19 in bovine and human pulmonary microvascular endothelial cells in situ. Comp Biochem Physiol Comp Physiol. 1993;104:313-319.
33. Dodge AB, Patton WF, Yoon MU, et al. Organ and species specific differences in cytoskeletal protein profiles of cultured microvascular endothelial cells. Comp Biochem Physiol B. 1991;98:461-470.
34. Magro CM, Crowson AN. The cutaneous pathology associated with seropositivity for antibodies to SSA (Ro): a clinicopathologic study of 23 adult patients without subacute cutaneous lupus erythematosus. Am J Dermatopathol. 1999;21:129-137.
35. Bowyer SL, Ragsdale CG, Sullivan DB. Factor VIII related antigen and childhood rheumatic diseases. J Rheumatol. 1989;16:1093-1097.
36. Kobayashi O. An electron microscopic study of the pulmonary alveolar capillaries in idiopathic interstitial pneumonia and lungs of collagen vascular diseases. Nihon Kyobu Shikkan Gakkai Zasshi. 1991;29:1007-1016.
37. Cohen S. Idiopathic pulmonary hemosiderosis. Am J Med Sci. 1999;317:67-74.
38. Schwarz MI, Matthay RA, Sahn SA, et al. Interstitial lung disease in polymyositis and dermatomyositis: analysis of six cases and review of the literature. Medicine. 1976;55:89-104.
39. Steen VD, Medsger TA Jr. Severe organ involvement in systemic sclerosis with diffuse scleroderma. Arthritis Rheum. 2000;43:2437-2444.
40. Boulware DW, Hedgpeth MT. Lupus pneumonitis and anti-SSA(Ro) antibodies. J Rheumatol. 1989;16:479-481.
41. Hedgpeth MT, Boulware DW. Interstitial pneumonitis in antinuclear antibody-negative systemic lupus erythematosus: a new clinical manifestation and possible association with anti-Ro (SS-A) antibodies. Arthritis Rheum. 1988;31:545-548.
42. Bernstein RM, Morgan SH, Chapman J, et al. Anti-Jo-1 antibody: a marker for myositis with interstitial lung disease. Br Med J (Clin Res Ed). 1984;289:151-152.
43. Wiener-Kronish JP, Solinger AM, Warnock ML, et al. Severe pulmonary involvement in mixed connective tissue disease. Am Rev Respir Dis. 1981;124:499-503.
44. Al-Mayouf SM, Al-Eid W, Bahabri S, et al. Interstitial pneumonitis and air leakage in juvenile dermatomyositis. Rheumatology (Oxford). 2001;40:588-590.
45. Kajihara M, Kuwana M, Tokuda H, et al. Myositis and interstitial lung disease associated with autoantibody to a transfer RNA-related protein Wa. J Rheumatol. 2000;27:2707-2710.
46. Lanto B, Bohm F, Meffert H, et al. The cytotoxic effect of anti-Ro- (SS-A) antibodies and UVA light on human endothelial cells in vitro [in German]. Dermatol Monatsschr. 1990;176:305-311.
47. Inoue T, Okamura M, Negoro N, et al. Anti-Ro/SS-A antibody-positive interstitial pneumonitis in a non-lupus patient. Osaka City Med J. 1994;40:117-120.
48. Friedman AW, Targoff IN, Arnett FC. Interstitial lung disease with autoantibodies against aminoacyl-tRNA synthetases in the absence of clinically apparent myositis. Semin Arthritis Rheum. 1996;26:459-467.
49. Atsumi T, Ieko M, Bertolaccini ML, et al. Association of autoantibodies against the phosphatidylserine-prothrombin complex with manifestations of the antiphospholipid syndrome and with the presence of lupus anticoagulant. Arthritis Rheum. 2000;43:1982-1993.
50. Matsubayashi H, Sugi T, Arai T, et al. Different antiphospholipid antibody specificities are found in association with early repeated pregnancy loss versus recurrent IVF-failure patients. Am J Reprod Immunol. 2001;46:323-329.
51. Kremmer S, Kreuzfelder E, Klein R, et al. Antiphosphatidylserine antibodies ate elevated in normal tension glaucoma. Clin Exp Immunol. 2001;125:211-215.
52. Jansen NL, Snell JR, Moy JN. Myocardial infarction as the presenting manifestation of systemic lupus erythematosus with antiphosphatidylserine antibodies. Ann Allergy Asthma Immunol. 1996;76:266-268.
53. Yodfat O, Blank M, Krause I, et al. The pathogenic role of anti-phosphatidylserine antibodies: active immunization with the antibodies leads to the induction of antiphospholipid syndrome. Clin Immunol Immunopathol. 1996;78:14-20.
54. Lin L, Shroyer L, Walter A, et al. Monoclonal IgM antiphosphatidylserine antibody reacts against cytoskeleton-like structures in cultured human umbilical cord endothelial cells. Am J Reprod Immunol. 1995;33:97-107.
55. Casao MA, Diaz R, Orduna A, et al. Promotion of platelet aggregation by sera from brucellosis patients with antiphosphatidylcholine antibodies. J Med Microbiol. 2001;50:965-968.
56. Tektonidou MG, Petrovas CA, loannidis JP, et al. Clinical importance of antibodies against platelet activating factor in antiphospholipid syndrome manifestations. Eur J Clin Invest. 2000;30:646-652.
57. Cocca BA, Seal SN, D'Agnillo P, et al. Structural basis for autoantibody recognition of phosphatidylserine-beta 2 glycoprotein 1 and apoptotic cells. Proc Natl Acad Sci U S A. 2001;98:13826-13831.
58. Sorice M, Circella A, Misasi R, et al. Cardiolipin on the surface of apoptotic cells as a possible trigger for antiphospholipids antibodies. Clin Exp Immunol. 2000;122:277-284.
59. Hill MB, Phipps JL, Hughes P, et al. Anti-endothelial cell antibodies in primary antiphospholipid syndrome and SLE: patterns of reactivity with membrane antigens on microvascular and umbilical venous cell membranes. Br J Haematol. 1998;103:416-421.
60. Meyer MF, Hellmich B, Kotterba S, et al. Cytomegalovirus infection in systemic necrotizing vasculitis: causative agent or opportunistic infection? Rheumatol Int. 2000;20:35-38.
61. Fernandes SR, Bertolo MB, Rossi CL, et al. Polyarteritis nodosa and cytomegalovirus: diagnosis by polymerase chain reaction. Clin Rheumatol. 1999;18:501-503.
62. Doherty M, Bradfield JW. Polyarteritis nodosa associated with acute cytomegalovirus infection. Ann Rheum Dis. 1981;40:419-421.
63. Mandell BF, Calabrese LH. Infections and systemic vasculitis. Curr Opin Rheumatol. 1998;10:51-57.
64. Wang J, Marker PH, Belcher JD, et al. Human cytomegalovirus immediate early proteins upregulate endothelial p53 function. FEBS Lett. 2000;474:213-216.
65. Kovacs A, Weber ML, Burns LJ, et al. Cytoplasmic sequestration of p53 in cytomegalovirus-infected human endothelial cells. Am J Pathol. 1996;149:1531-1539.
66. Knight DA, Waldman WJ, Sedmak DD. Cytomegalovirus-mediated modulation of adhesion molecule expression by human arterial and microvascular endothelial cells. Transplantation. 1999;68:1814-1818.
67. Wang J, Belcher JD, Marker PH, et al. Cytomegalovirus inhibits p53 nuclear localization signal function. J Mol Med. 2001;78:642-647.
68. Waldman WJ, Knight DA. Cytokine-mediated induction of endothelial adhesion molecule and histocompatibility leukocyte antigen expression by cytomegalovirus-activated T cells. Am J Pathol. 1996;148:105-119.